AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

Pharma investors reeled this week from reports that AstraZeneca held merger talks with U.S. rival Bristol Myers Squibb, a move that would break from Big Pharma's decade-long strategy of acquiring smaller companies.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.